# A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

Source: https://onco.cc/trials/nct06265428/  
OnCo record `nct06265428` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab pamirtecan run by DualityBio Inc. in her2-positive breast cancer, active.

## Summary

A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer is a phase 3 interventional study registered as NCT06265428 by DualityBio Inc., with 228 participants enrolled, started 2024-01-29. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06265428
- Phase: 3
- Setting: A Phase III, Multicenter, Open-label, Randomized Study to Compare DB-1303 Versus T-DM1 in Patients With HER2-positive Unresectable/Metastatic Breast Cancer Who Have Been Treated With Trastuzumab and a Taxane (Dynasty-Breast01)
- Sponsor: DualityBio Inc.
- Enrolled: 228

## Sources

- ClinicalTrials.gov NCT06265428: https://clinicaltrials.gov/study/NCT06265428

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Trastuzumab pamirtecan](https://onco.cc/drugs/trastuzumab-pamirtecan/)
- companies: [Duality Biotherapeutics](https://onco.cc/companies/dualitybio/)

---
JSON: https://onco.cc/api/v1/entities/nct06265428.json